| Autor: |
Mellacheruvu S; Department of Hematology and Oncology, St John's Riverside Hospital, Yonkers, NY.; Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY., Sayegh MN; Department of Hematology and Oncology, St John's Riverside Hospital, Yonkers, NY., Sica RA; Division of Hematologic Malignancies, Department of Oncology, Montefiore Medical Center, Bronx, NY., Cheng H; Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY., Santos-Zabala ML; Department of Anatomic and Clinical Pathology, St John's Riverside Hospital, Yonkers, NY., Gebrael JH; Department of Radiology, St John's Riverside Hospital, Yonkers, NY., Hermanto U; Department of Radiation Oncology, Montefiore Yonkers Radiation Oncology, Yonkers, NY., Rosen NL; Department of Hematology and Oncology, St John's Riverside Hospital, Yonkers, NY. |
| Abstrakt: |
Competing Interests: R. Alejandro SicaConsulting or Advisory Role: MorphoSys AG Haiying ChengConsulting or Advisory Role: AstraZeneca, BayerResearch Funding: Roche/Genentech, Spectrum Pharmaceuticals, VaccinexPatents, Royalties, Other Intellectual Property: Patent pendingNo other potential conflicts of interest were reported. |
